Abstract: The present invention(s) provide systems and methods for identifying one or more long-term health conditions that a patient may be suffering from, and providing an appropriate intervention plan for managing the health condition. In addition, the present invention(s) provide systems and methods for prioritizing among various potential long-term health conditions that a patient may suffer from, and provide an appropriately prioritized intervention plan for managing a variety of health conditions. Finally, the present invention(s) provide systems and methods for continuously monitoring patient health and/or outcome data to appropriately change an intervention plan based on the specific response that may be exhibited by a patient. In this manner the present invention(s) provide a systematized approach for managing long-term health conditions that previously required guesswork and continuous trial and error.

Abstract: The present invention(s) provide systems and methods for identifying one or more long-term health conditions that a patient may be suffering from, and providing an appropriate intervention plan for managing the health condition. In addition, the present invention(s) provide systems and methods for prioritizing among various potential long-term health conditions that a patient may suffer from, and provide an appropriately prioritized intervention plan for managing a variety of health conditions. Finally, the present invention(s) provide systems and methods for continuously monitoring patient health and/or outcome data to appropriately change an intervention plan based on the specific response that may be exhibited by a patient. In this manner the present invention(s) provide a systematized approach for managing long-term health conditions that previously required guesswork and continuous trial and error.

Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.

Abstract: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Novel aglycosylated antibodies having a binding affinity for the Cd3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

Abstract: Inducing tolerance in a primate by use of a compound that has certain characteristics when tested in vitro. The compound is preferably TRX1 antibody and the compound is preferably used in accordance with a specified dosing regimen.